Revvity (NYSE:RVTY) Downgraded to “Strong Sell” Rating by Zacks Research

Zacks Research cut shares of Revvity (NYSE:RVTY) from a hold rating to a strong sell rating in a research report sent to investors on Monday morning,Zacks.com reports.

Several other brokerages have also recently issued reports on RVTY. The Goldman Sachs Group dropped their price target on Revvity from $110.00 to $95.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 14th. Sanford C. Bernstein initiated coverage on shares of Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 target price on the stock. Robert W. Baird set a $117.00 price objective on Revvity in a report on Wednesday, May 6th. Weiss Ratings upgraded Revvity from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. Finally, TD Cowen increased their target price on Revvity from $115.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $108.92.

Revvity Trading Down 0.7%

NYSE:RVTY opened at $112.15 on Monday. The stock’s 50 day moving average price is $100.42 and its 200 day moving average price is $98.36. The company has a market capitalization of $12.51 billion, a PE ratio of 53.66, a P/E/G ratio of 2.47 and a beta of 1.09. Revvity has a 52-week low of $81.22 and a 52-week high of $118.30. The company has a quick ratio of 1.41, a current ratio of 1.72 and a debt-to-equity ratio of 0.37.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The firm had revenue of $711.12 million during the quarter, compared to analysts’ expectations of $704.07 million. During the same quarter in the prior year, the business earned $1.01 EPS. Revvity’s quarterly revenue was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, research analysts anticipate that Revvity will post 5.25 EPS for the current year.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, July 17th. Revvity’s dividend payout ratio (DPR) is presently 13.40%.

Institutional Investors Weigh In On Revvity

Institutional investors and hedge funds have recently modified their holdings of the company. EdgePoint Investment Group Inc. boosted its position in shares of Revvity by 26.3% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 8,574,280 shares of the company’s stock worth $751,536,000 after buying an additional 1,784,620 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Revvity by 127.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,751,612 shares of the company’s stock valued at $171,921,000 after acquiring an additional 980,142 shares in the last quarter. Norges Bank acquired a new position in Revvity during the fourth quarter worth about $80,382,000. Morgan Stanley raised its position in Revvity by 29.6% during the fourth quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock worth $275,202,000 after acquiring an additional 650,083 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in shares of Revvity by 7.0% in the fourth quarter. Janus Henderson Group PLC now owns 8,161,171 shares of the company’s stock valued at $789,595,000 after purchasing an additional 533,912 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.